Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Departments

Anticoagulation for atrial fibrillation (January 2017)

Elise Henning, MD, MED
Cleveland Clinic Journal of Medicine September 2017, 84 (9) 658; DOI: https://doi.org/10.3949/ccjm.84c.09001
Elise Henning
Geriatric Medicine Fellow, University of Cincinnati/Christ Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: As a geriatric medicine fellow, I eagerly read Hagerty and Rich’s review “Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance”1 and Suh’s editorial, “Whether to anticoagulate: Toward a more reasoned approach”2 in the January 2017 issue. Both pieces were helpful and informative.

I appreciate that Dr. Suh encourages shared decision-making between physicians and patients that balances patient preferences and risk stratification to inform whether to anticoagulate. He states, “Unfortunately, there is no similar screening tool to predict bleeding risk from anticoagulation with greater precision in the middle to lower part of the risk spectrum…The patient’s life expectancy and personal preferences are important independent factors that affect the decision of whether to anticoagulate or not.”

Dr. Mark Eckman’s Atrial Fibrillation Decision Support Tool (AFDST) incorporates patients’ CHA2DS2-VASc and HAS-BLED scores to determine their quality-adjusted life expectancy on or off anticoagulation. The tool helps guide physicians and patients to make shared decisions about anticoagulation.3–5 The AFDST informs clinicians if a patient is undertreated or being treated unnecessarily. Eckman and his colleagues have demonstrated the AFDST’s effective application in clinical practice, including for older adults. I invite readers to learn more about Eckman’s work!

  • Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Hagerty T,
    2. Rich MW
    . Fall risk and anticoagulation for atrial fibrillation in the elderly: a delicate balance. Cleve Clin J Med 2017; 84:35–40.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Suh TT
    . Whether to anticoagulate: toward a more reasoned approach. Cleve Clin J Med 2017; 84:41–42.
    OpenUrlFREE Full Text
  3. ↵
    1. Eckman MH,
    2. Lip GYH,
    3. Wise RE,
    4. et al
    . Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am Heart J 2016; 176:17–27.
    OpenUrlCrossRefPubMed
    1. Eckman MH,
    2. Wise RE,
    3. Speer B,
    4. et al
    . Integrating realtime clinical information to provide estimates of net clinical benefit antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014; 7:680–686.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Eckman MH,
    2. Lip TYH,
    3. Wise RE,
    4. et al
    . Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc 2016; 64:1054–1060.
    OpenUrl
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 84 (9)
Cleveland Clinic Journal of Medicine
Vol. 84, Issue 9
1 Sep 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anticoagulation for atrial fibrillation (January 2017)
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anticoagulation for atrial fibrillation (January 2017)
Elise Henning
Cleveland Clinic Journal of Medicine Sep 2017, 84 (9) 658; DOI: 10.3949/ccjm.84c.09001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anticoagulation for atrial fibrillation (January 2017)
Elise Henning
Cleveland Clinic Journal of Medicine Sep 2017, 84 (9) 658; DOI: 10.3949/ccjm.84c.09001
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Departments

  • Our Peer-Reviewers For 2022
  • An unexpected turn
  • Extraosseous calcification in kidney disease
Show more Departments

Letters to the editor

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
  • In Reply: Antiobesity drug therapy
Show more Letters to the editor

Similar Articles

Subjects

  • Neurology
  • Geriatrics
  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire